BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drenth JP, Schattenberg JM. The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opinion on Investigational Drugs 2020;29:1365-75. [DOI: 10.1080/13543784.2020.1839888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Gharanei S, Shabir K, Brown JE, Weickert MO, Barber TM, Kyrou I, Randeva HS. Regulatory microRNAs in Brown, Brite and White Adipose Tissue. Cells 2020;9:E2489. [PMID: 33207733 DOI: 10.3390/cells9112489] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
2 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Reference Citation Analysis]
3 Helmstädter M, Schmidt J, Kaiser A, Weizel L, Proschak E, Merk D. Differential Therapeutic Effects of FXR Activation, sEH Inhibition, and Dual FXR/sEH Modulation in NASH in Diet-Induced Obese Mice. ACS Pharmacol Transl Sci 2021;4:966-79. [PMID: 33860214 DOI: 10.1021/acsptsci.1c00041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Youhanna S, Kemas AM, Preiss L, Zhou Y, Shen JX, Cakal SD, Paqualini FS, Goparaju SK, Shafagh RZ, Lind JU, Sellgren CM, Lauschke VM. Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives. Pharmacol Rev 2022;74:141-206. [PMID: 35017176 DOI: 10.1124/pharmrev.120.000238] [Reference Citation Analysis]
5 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Baumann A, Nier A, Hernández-Arriaga A, Brandt A, Lorenzo Pisarello MJ, Jin CJ, Pilar E, Camarinha-Silva A, Schattenberg JM, Bergheim I. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Sci Rep 2021;11:17815. [PMID: 34497333 DOI: 10.1038/s41598-021-97346-9] [Reference Citation Analysis]
7 Liang C, Li J, Tian B, Tian L, Liu Y, Li J, Xin L, Wang J, Fu C, Shi Z, Xia J, Liang Y, Wang K. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Biomed Pharmacother 2021;144:112298. [PMID: 34649219 DOI: 10.1016/j.biopha.2021.112298] [Reference Citation Analysis]
8 Bianco C, Casirati E, Malvestiti F, Valenti L. Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. JHEP Rep 2021;3:100284. [PMID: 34027340 DOI: 10.1016/j.jhepr.2021.100284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Reference Citation Analysis]
10 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
11 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]